Description: Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. The company markets JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, a JAK inhibitor, which is in Phase III clinical trial for polycythemia vera; Phase II trial for essential thrombocythemia; Phase II trial for pancreatic cancer; Phase I/II trial to treat solid tumors/other hematologic malignancies, as well as baricitinib, a JAK inhibitor, which is Phase III trial for rheumatoid srthritis, Phase IIb trial for psoriasis, and Phase II trial for diabetic nephropathy. The company's products in pipeline also comprise INCB28060 and INCB24360, which are Phase II clinical trial products for the treatment of solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Home Page: www.incyte.com
INCY Technical Analysis
1801 Augustine Cut-Off
Wilmington,
DE
19803
United States
Phone:
302 498 6700
Officers
| Name | Title |
|---|---|
| Mr. Herve Hoppenot | Chairman, Pres & CEO |
| Ms. Christiana Stamoulis MBA | Exec. VP & CFO |
| Ms. Maria E. Pasquale J.D. | Exec. VP, Gen. Counsel & Corp. Sec. |
| Dr. Barry P. Flannelly M.B.A., MBA, Pharm.D. | Exec. VP & GM of North America |
| Dr. Steven H. Stein M.D. | Exec. VP & Chief Medical Officer |
| Mr. Thomas Tray | VP of Fin., Chief Accounting Officer & Controller |
| Mr. Michael James Morrissey | Exec. VP & Head of Global Technical Operations |
| Dr. Dashyant Dhanak Ph.D. | Exec. VP & Chief Scientific Officer |
| Ms. Christine Chiou | Head of Investor Relations |
| Ms. Pamela M. Murphy | VP of Investor Relations & Corp. Communications |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 14.9477 |
|---|---|
| Trailing PE: | 20.1071 |
| Price-to-Book MRQ: | 3.8229 |
| Price-to-Sales TTM: | 5.4924 |
| IPO Date: | 1993-11-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 2094 |